These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19199909)

  • 1. Reducing the immunogenicity of protein therapeutics.
    Onda M
    Curr Drug Targets; 2009 Feb; 10(2):131-9. PubMed ID: 19199909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.
    Kaumaya PT; Kobs-Conrad S; Seo YH; Lee H; VanBuskirk AM; Feng N; Sheridan JF; Stevens V
    J Mol Recognit; 1993 Jun; 6(2):81-94. PubMed ID: 7508238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of protein therapeutics.
    De Groot AS; Scott DW
    Trends Immunol; 2007 Nov; 28(11):482-90. PubMed ID: 17964218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and removal of immunogenicity in therapeutic proteins.
    Baker MP; Jones TD
    Curr Opin Drug Discov Devel; 2007 Mar; 10(2):219-27. PubMed ID: 17436557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation.
    Jawa V; Cousens LP; Awwad M; Wakshull E; Kropshofer H; De Groot AS
    Clin Immunol; 2013 Dec; 149(3):534-55. PubMed ID: 24263283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of a chimeric peptide corresponding to T helper and B cell epitopes of the Chlamydia trachomatis major outer membrane protein.
    Su H; Caldwell HD
    J Exp Med; 1992 Jan; 175(1):227-35. PubMed ID: 1370528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico analysis of MHC-I restricted epitopes of Chikungunya virus proteins: Implication in understanding anti-CHIKV CD8(+) T cell response and advancement of epitope based immunotherapy for CHIKV infection.
    Pratheek BM; Suryawanshi AR; Chattopadhyay S; Chattopadhyay S
    Infect Genet Evol; 2015 Apr; 31():118-26. PubMed ID: 25643869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the immunogenicity of protein drugs by applying in vitro MHC binding data and the immune epitope database and analysis resource.
    Paul S; Kolla RV; Sidney J; Weiskopf D; Fleri W; Kim Y; Peters B; Sette A
    Clin Dev Immunol; 2013; 2013():467852. PubMed ID: 24222776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [MHC tetramers: tracking specific immunity].
    Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
    Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020.
    Jawa V; Terry F; Gokemeijer J; Mitra-Kaushik S; Roberts BJ; Tourdot S; De Groot AS
    Front Immunol; 2020; 11():1301. PubMed ID: 32695107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hierarchic T-cell help to non-linked B-cell epitopes.
    Brons NH; Blaich A; Wiesmüller KH; Schneider F; Jung G; Muller CP
    Scand J Immunol; 1996 Nov; 44(5):478-84. PubMed ID: 8947599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential order of T and B cell epitopes affects immunogenicity but not antibody recognition of the B cell epitope.
    Denton G; Hudecz F; Kajtár J; Murray A; Tendler SJ; Price MR
    Pept Res; 1994; 7(5):258-64. PubMed ID: 7531518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of the T-helper epitope on the titre and affinity of antibodies to B-cell epitopes after co-immunization.
    Shaw DM; Stanley CM; Partidos CD; Steward MW
    Mol Immunol; 1993 Aug; 30(11):961-8. PubMed ID: 7688851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epitopes of the class I major histocompatibility complex (MHC-I) recognized in the syngeneic or allogeneic context predominantly linked to antigenic peptide loading to its binding groove.
    Nguyen van Binh P; Duc HT
    Clin Exp Immunol; 2006 Aug; 145(2):372-9. PubMed ID: 16879259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics.
    Nagata S; Pastan I
    Adv Drug Deliv Rev; 2009 Sep; 61(11):977-85. PubMed ID: 19679153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of immunogenicity of therapeutic proteins: validity of computational tools.
    Bryson CJ; Jones TD; Baker MP
    BioDrugs; 2010 Feb; 24(1):1-8. PubMed ID: 20055528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety.
    Schödel F; Peterson D; Milich D
    Intervirology; 1996; 39(1-2):104-10. PubMed ID: 8957676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-helper epitopes identified within the E6 transforming protein of cervical cancer-associated human papillomavirus type 16.
    Azoury-Ziadeh R; Herd K; Fernando GJ; Frazer IH; Tindle RW
    Viral Immunol; 1999; 12(4):297-312. PubMed ID: 10630789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of available design space for identification of non-immunogenic protein therapeutics.
    Lee SC
    Biomed Microdevices; 2010 Apr; 12(2):283-6. PubMed ID: 20012559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of orientation and number of copies of T and B cell epitopes on the specificity and affinity of antibodies induced by chimeric peptides.
    Partidos C; Stanley C; Steward M
    Eur J Immunol; 1992 Oct; 22(10):2675-80. PubMed ID: 1382995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.